1392275-56-7Relevant articles and documents
Practical synthesis, separation, and stereochemical assignment of the PMPA pro-drug GS-7340
Chapman,Kernan,Prisbe,Rohloff,Sparacino,Terhorst,Yu
, p. 621 - 628 (2001)
The practical synthesis of a mixed phenoxy-amidate derivative of PMPA with high oral bioavailability and favorable pharmacokinetics is described. The non-stereoselective synthetic route produces a 1:1 mixture of two diastereomers at phosphorous. Simulated moving bed chromatography using Chiralpak AS enabled kilo-scale isolation of the more potent diastereomer (GS-7340). The GS-7340 phosphorous chiral center was found to be (S) by X-ray crystallography.
Method for preparing antiviral drug tenofovir alafenamide fumarate
-
, (2022/04/09)
The invention discloses a method for preparing an antiviral drug tenofovir alafenamide fumarate, which comprises the following steps of: (1) reacting adenine with (R)-propylene carbonate to generate a compound I; (2) treating the compound I with magnesium tert-butoxide, and then adding phosphonate S to react to obtain a compound II; (3) the compound III is obtained by hydrolyzing the compound II in hydrobromic acid; (4) reacting the compound III with thionyl chloride to obtain phosphonyl chloride, and directly reacting the phosphonyl chloride with L-alanine isopropyl ester without purification to generate a compound IV; and (5) obtaining a final product, wherein the preparation of the propionyl phenol fumarate tenofovir is completed by salifying the compound IV and fumaric acid. The method has the advantages of few synthetic route steps, mild reaction conditions and principle saving, and can improve the yield of the final product.
CRYSTAL FORM OF TENOFOVIR ALAFENAMIDE SALT, PREPARATION METHOD AND USE THEREOF
-
Paragraph 0039; 0040; 0041; 0042; 0043; 0044; 0045-0053, (2019/04/18)
Disclosed are a new polymorph II, crystal form A and B of 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine fumarate, and preparation methods and pharmaceutical use thereof. The crystal form II is a hemi-fumarate; the crystal form A is a mono-fumarate; and the crystal form B is a sesqui-fumarate. Compared with the existing crystal form, the new crystal forms have obvious advantages in solubility, stability and preparation process.